August 2022 Joint Technical Work Group Recaps:

For results of Data Element Request Forms (DERFs) and External Code List (ECLs) reviewed see DERF Resolution at [https://member.ncpdp.org/work-groups.aspx?ID=wgmc](https://member.ncpdp.org/work-groups.aspx?ID=wgmc).

**Work Group 1 Telecommunication**

DERFs/ECLs Reviewed:
- DERF 001906/Emergency ECL 000374 was withdrawn.
- DERF 001907/ECL 000375 was recommended to MC to pend.
- DERF 001908/ECL 000376 was recommended to MC to pend.
- DERF 001909/ECL 000377 was recommended to MC to approve.
- DERF 001910/ECL 000378 was recommended to MC to approve.
- DERF 001911/ECL 000379 was recommended to MC to approve as modified.
- DERF 001912/ECL 000380 was recommended to MC to approve as modified.

Task Groups:
- The **Telecommunication FAQ Task Group** reviewed two DERFs and one Frequently Asked Question (FAQ). The Patient Gender Code question and answer was modified and approved as modified for inclusion in *Telecommunication Version D and Above Questions, Answers and Editorial Updates*.
- The **P and C/WC Monitoring, Billing and Education Task Group** provided an update of legislative and regulatory developments from the last quarter.
- The **Coordination of Benefits (COB) Task Group** created and completed COB FAQ 96 – State Agency COB and OCC Clarification and COB FAQ 97 – Use of OPPRA in Government COB. The task group worked on a webinar that will be presented August 12th and began drafting F6 guidance for patient pay components and tax fields.
- The **Information Reporting Problems Task Group** worked with RelayHealth to have the new payer sheet for N transactions added to the MediFacD website. The task group continued monitoring the Wisconsin State Pharmaceutical Assistance Program (SPAP) project in conjunction with the WG9 COBC/BCRC Task Group. They also created DERF 001910/ECL 000378 for N Transaction Payer Identification Segment Rejects.
- The **Definition of a Valid Prescriber Task Group** created DERF 001908/ECL 000376 requesting updates to Reject Code (511-FB) and RejectCode values 777 and DERF 001909/ECL 00377 requesting updates to Data Source of Invalid Provider Determination (E87-ZV) values due to changes in data sources. The task group continued working on updates to the provider information in the *Telecommunication Version D and Above Questions, Answers and Editorial Updates*.
- The **Benefit Integration Task Group** reviewed an examples document for benefit synchronization. They continued to review related documents corresponding with the changes made for transaction format layout, examples document and implementation guide. They also began drafting a benefit integration white paper.
• The **Clinical and Safety Edits Task Group** continued their review of the DUR codes and is working on DERFs to modify some definitions and sunset some codes. They will begin creating additional guidance for some of the codes next quarter.

• The **Telecommunication Agility Next Generation (TANG) Task Group** discussed training deliverables include timing, audience, topics and format.

• The **Pharmacy Services Billing Task Group** continued drafting a white paper to outline recommendations on the use of NCPDP Telecommunication Standard vD.0 Service Billing Transactions (S1, S2, S3) to address current gaps with pharmacist professional service claim adjudication processes. They also created a topics document to track discussion around specific topics and new business cases as they are presented.

• The **Eligibility Verification Enhancements Task Group** reviewed the Telecommunication Standard Version F6 E1 payer sheets for Medicare Part A/B and Part D. The Medicare Part D E1 payer sheet is now named *NCPDP Version F6 E1 Specifications for Medicare Manage Care (Drug and Medical)* and defines which plan types are included in Medicare Managed Care. The task group has decided to echo back the Date of Service (401-D1) in Other Benefit Detail Information Effective Date (D28-MM) field.

• The **Expand Dollar Fields Task Group** did not meet this quarter.

• The **Post Adjudication Task Group** did not meet this quarter.

• The **Standardized Subrogation Task Group** did not meet this quarter.

**Other Reportables:**

• **DSMO Change Requests:** There is no update on the status of the DSMO Change Request 1201 (New Version of the Batch Standard), 1202 (New Standard - Subrogation Implementation Guide for Batch Standard) and 1208 (New Version of the Telecommunication Standard). The Division of National Standards (DNS) is working on the Notice of Proposed Rulemaking (NPRM).

• **MC Prior Authorization Communication, Evaluation and Recommendations Task Group** and the **SNIP Committee:** Received updates on the work of the task group and the committee.

• **MC RTPB Standard Task Group and MC REMS Workflow to Transaction Task Group:** Recaps for these task groups can be found in the WG1 download materials.

**New Business:**

• The **WG1 Scope and Goals** were reviewed and approved as modified.

**Work Group 2 Product Identification**

**Task Groups:**

• The **Product Review and Billing Unit Exception Task Group** reviewed issues resulting from changes to existing products or to the release of new products. The task group:
  
  o Reviewed and submitted to WG2 for adjudication two new QUIC forms (See final adjudication determination by the work group in this report):
    
    • QUIC # 202201 Verrica VP-102
    
    • QUIC # 202202 Sevenfact® *(was reviewed by the task group on July 26, 2022, and will be voted on at November 2022 Work Group)*

  o Reviewed one product via email and one during a task group call for verification of the package size or billing unit to list within the drug compendia files.

  o Heard a presentation from the National Association of Chain Drug Stores (NACDS) regarding preparation for the commercialization of COVID-19 vaccinations.

  o Heard a presentation from the United States Pharmacopeia (USP) and NACDS about standardization of compound formulations and Compound Formulation Identifiers (CFID).
o Sent a letter to Sanofi re: Single Product Identifier (NDC) on External Packaging When COVID-19 Vaccine is Commercially Approved. The letter requested external packaging of the vaccine contain a single product identifier (i.e., NDC) with the final volume on the label when the commercial product is approved.

o Completed review of products on the specific non-drug spreadsheet. Updates to billing unit and package size on products containing self-adhesive wraps, bandages and occlusive dressings were completed June 1, 2022.

o Reviewed and updated the notification letter to impacted radiopharmaceutical manufacturers that was pended back to the task group for additional work following a review by WG2 in May. The letter has been updated to include information regarding Centers for Medicare and Medicaid Services (CMS) notification. Coordination of billing unit change for those products listed with a billing unit of ML is planned to be completed by September 30, 2022.

o For April through June 2022, 3,541 new Structured Product Label (SPL) Billing Unit Index files were generated with four changed SPL Billing Unit Index files based on the files received by the Food and Drug Administration (FDA) from the compendia. The compendia group has reconciled 17 of the 23 NDCs with discrepancies.

o At November 2022 Work Group, there will be a joint discussion with the MC NDC Scarcity Task Group to review and approve NCPDP’s comments for the Notice of Proposed Rulemaking (NPRM) – Revising the National Drug Code Format and Drug Label Barcode Requirements.

- The Naming Standards for Drugs, Biologics and Biosimilars Task Group reviewed operational issues with interchangeable biosimilars with multiple reference products but only one interchangeable product and other issues concerning multiple interchangeable uses. The task group:

  o Heard a presentation by Tammy Powell of the National Library of Medicine (NLM) who led a discussion on how RxNorm might be leveraged to support data relationships for interchangeable products from a substitution perspective.

  o Reviewed insulin glargine. The FDA’s Purple Book has four reference products and one biosimilar (Semglee) that is interchangeable with the reference product, Lantus.

  o Reviewed adalimumumab. The FDA’s Purple Book has six biosimilar products but only one biosimilar (Cyltezo) that is interchangeable with the only reference product, Humira. In addition, the interchangeable Cyltezo has seven interchangeable uses.

  o Discussed concerns about the absence of data for unbranded biologics and the indication of specific relationships for interchangeable products with the Purple Book that need to be brought to the FDA’s attention.

- The Outsourcing Facility Task Group will continue monitoring the FDA committee that is exploring options to include current information offered in the FDA database to the National Institutes of Health (NIH) and DailyMed to facilitate the automatic transfer of data in the usual and customary data file format to make the information accessible to stakeholders.

Other Reportables:

- **MC REMS Workflow to Transaction Task Group, MC Digital Therapeutics Task Group and MC NDC Scarcity Task Group:** Recaps for these task groups can be found in the WG2 download materials.

New Business:

- New QUIC Form Review and Final Adjudication:
  o QUIC #202201 Verrica VP-102
BU=EA and Quantity 1 x the number of single dose applicators supplied in the package per 5.2.1 and 5.1.12 of the Billing Unit Standard.

- The **WG2 Scope and Goals** were reviewed, modified and approved as modified.
- Ed Millikan of the FDA provided information on Paxlovid dosing and prescribing medication error that is occurring in ePrescribing and electronic health record (EHR) systems that can stream into pharmacy information management systems and potentially affect patient outcomes.

**Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards**

**Task Groups:**
- The **Manufacturer Rebate Standard Task Group** discussed challenges with rebills and ways to improve the data, including potentially adding a new data element to identify the source of a reversal, modifying the Manufacturer Rebates Standard and creating future DERFs.
- The **Medical Rebate Standard Task Group** did not meet this quarter but will be coming off hiatus and meeting every other Wednesday at 1:00 p.m. CDT. The first meeting is scheduled for August 24, 2022.

**New Business:**
- The **WG7 2022-2023 Scope and Goals** were reviewed and approved as modified.

**Work Group 9 Government Programs**

**Task Groups:**
- The **Prescription Drug Monitoring Programs Task Group** continued monitoring state PMP activity and updated the State PMP Tracking Document, which was approved by WG9.
- The **Coordination of Benefits Contractor (COBC)/Benefits Coordination and Recovery Center (BCRC) Task Group** continued to work with RelayHealth, Wisconsin SPAP and CMS on the remediation plan to correct the OHI and apply the N transactions correctly by creating a unique BIN/PCN for qualified versus non-qualified plans. The task group developed an FAQ and an NCPDP-hosted webinar, which took place on May 25, 2022. The task group requested and received approval from WG9 to publish the WI SPAP FAQ document. The task group requested approval to change the task group name and scope statement. Further modifications to the task group name and scope statement will be made at the task group level and presented for approval during the November Work Group meeting.
  - The **Chapter 14 Review Sub-Task Group** submitted the modified Chapter 14 document to CMS for review. The sub-task group is awaiting feedback from CMS.
- The **Hospice Task Group** collaborated with RelayHealth on the hospice portion of the MediFacD website to modify verbiage, documentation and design. The task group also developed an NCPDP-hosted webinar, which took place on June 29, 2022. The task group requested and received approval from WG9 to modify the task group scope statement.
- The **Medicare Financial Information Reporting (FIR) Task Group** created an editorial document which contains FIR scenarios. The editorial document will be completed in the upcoming quarter and presented for approval during the November Work Group meeting.
- The **Medicare Part D Frequently Asked Questions Task Group** reviewed the CMS memo ‘Proposed Updates to the Prescription Drug Event (PDE) File Layout’ and collaborated with the WG9 Medicare Prescription Drug Event (PDE) Task Group to develop feedback to submit to CMS. The task group created and submitted DERFs 001911/ECL 000379 and 001912/ECL 000380. The task group will create an FAQ for both DERFs in the upcoming quarter.
The Medicare Part D Section 111 Issues and Questions Task Group identified reporting discrepancies from certain Responsible Reporting Entities (RREs) and continued to work with the BCRC to address issues.

The Medicare Prescription Drug Event (PDE) Task Group discussed and submitted comments to CMS on the CMS memo ‘Proposed Updates to the Prescription Drug Event (PDE) File Layout’, continued discussion on the identification of Medicaid Subrogation claims, reviewed and discussed the CMS memo ‘VBP Model Guidance on Treatment of Reductions in Part D Cost-Sharing’ and continued to prioritize outstanding questions for resubmission to CMS.

The Government Programs Encounter Reporting Standard Task Group did not meet this quarter.

The Medicaid Frequently Asked Questions Task Group did not meet this quarter.

The 340B Task Group did not meet this quarter.

The Medicare Standardized Fraud, Waste and Abuse Training Attestation Task Group did not meet this quarter.

New Business:

The WG9 2022-2023 Scope and Goals were reviewed and approved as modified.

Work Group 10 Professional Pharmacy Services

Task Groups:

The MTM and Pharmacist Clinical Services Task Group is still waiting for the HL7® Patient Care Work Group (PCWG) to ballot the Multiple Chronic Condition (MCC) eCare Plan summary FHIR® implementation guide profile for patients and clinical teams (MCC eCare Plan efforts). The task group completed work on a white paper recommending a Beneficiary Level Report (BLR) standard for exchange between the provider of the Medication Therapy Management (MTM) services to the Medicare Advantage Prescription Drug (MAPD) plans or stand-alone Prescription Drug Plans (PDPs), including identification of NCPDP and/or HL7® standards. In relation to the white paper, new DERFs are being created to introduce new Data Dictionary and External Code List entries for the NCPDP Telecommunication Standard to enhance listings in the white paper.

The Pharmacogenomics Task Group received an update on DERF 001894/ECL 000369, created by Xact Laboratories, which was approved as modified during the May Work Group meetings. The task group reviewed new pharmacogenomics (PGx) use cases related to pharmacy and laboratory PGx data exchanges.

The WG14/WG10 Standardized Medication Profile Task Group worked with the author of Project Development Form 56 (Create a specification for a defined data set fit for use in a Conformance Reconciled Medication List (C-RML) application currently in development), Dr. Reed Gelzer, project submitter, and his team have a management change, and the task group is working with the new management team on their request.

The Identification of Social Determinants of Health Task Group continued working on a white paper to address recommendations for social determinants of health in the pharmacy within NCPDP standards. They expect to present the white paper at the November Work Group meeting.

Other Reportables:

WG1 Pharmacy Services Billing Task Group and WG14 Consultant Pharmacist Interoperability Task Group: Updates on the work of these task groups were given.

WG18 Specialty Requirements for ePrescribing Task Group: The recap for this task group can be found in the WG10 download materials.

Industry Updates:

There was an update on USP Allergy Expert Panel and USP Compound Preparations Expert Panel presented by Cathy Graeff.
New Business:
- The **WG10 2022-2023 Scope and Goals** were reviewed and approved as modified.

**Work Group 11 ePrescribing & Related Transactions**

DERFs Reviewed:
- DERF 001901 was approved with modifications.
- DERF 001913 was approved with modifications.
- DERF 001914 was approved.
- DERF 001915 was approved.
- DERF 001916 was approved with modifications.

Task Groups:
- The **Dispensed Medication Reporting Task Group** did not meet this quarter.
- The **WG11 ePrescribing Regulatory Task Group** did not meet this quarter.
- The **Formulary and Benefit Task Group** brought forth DERF 001916 for the Formulary and Benefit Standard Version 60.
- The **Implementation of Structured Sig Task Group** reviewed questions received from an implementer and created additional examples to be included in the SCRIPT Examples Guide.
- The **Pharmacy Product Locator Task Group** completed a gap analysis of the Specialized CFProductInquiry and Response messages and the proposed transaction for the product locator tool.
- The **Pharmacy to Pharmacy Prescription Transfer Task Group** disbanded, having completed their work.
- The **Prior Authorization Workflow-to-Transactions Task Group** reviewed the ReasonCode value of “BY” (Other) and began guidance and tracking for opportunities to create additional codified values.
- The **SCRIPT Implementation Recommendations Task Group** brought forth DERFs 0019101 and 001915. They also received approval for two additions to the **SCRIPT Implementation Recommendations** document, and the address topic was pended to the task group.
  - The **RxChange Guidance Review Sub-Task Group** received approval to become a task group. The name will be RxChange Task Group.
- The **XML Task Group** continued working on streamlining the medication elements.
- The **WG14/WG11 LTPAC ePrescribing Task Group** continued looking at creating new MessageRequestSubCodes for use in the RxChange messages.

Other Reportables:
- SCRIPT Version 2017071 NSC-11 certified members were recognized.

New Business:
- The **WG11 2022-2023 Scope and Goals** were reviewed, modified and approved as modified.

**Work Group 14 Long Term and Post Acute Care (LTPAC)**

Old Business:
- Gary Schoettmer of NetRx, LLC provided a LTPAC industry update.

Task Groups:
- The **LTPAC Billing Issues Task Group** will continue working on Telecommunication Standard D.0 to F6 Transition Guidance for LTPAC. They will continue reviewing and updating the **Telecommunication Version D and Above Questions, Answers and Editorial Updates** for language related
to LTPAC Short Cycle and Submission Clarification Codes (SCC) to replace with LTPAC Dispense Frequency where applicable for Telecommunication Standard Version F6 guidance

- The **Consultant Pharmacist Interoperability Task Group** discussed creating a FHIR® Implementation Guide in place of the guidance document. The task group voted to continue with the guidance document for now.
- The **Long Term and Post Acute Care ePrescribing Task Group** continued discussing the LTPAC prescription change sub-categories and proposed optional codes to communicate the subcategory. The task group asked the WG14 audience for input on appropriateness of each code and expected action. Based on the results of a straw poll, WG14 agreed with the proposed changes. The task group will be revisiting discussions on the original workflows completed by the Multi-Communication Sub-Task Group.
- The **WG14/WG10 Standardized Medication Profile Task Group** will continue working on the on New Project Development Form 56 effort related to a patient’s interactive electronic medication list to assist with the provider’s medication reconciliation process.

Other Reportables:

- **WG1 Eligibility Verification Task Group**, **WG9 Medicare Part D FAQ Task Group**, **WG9 Hospice Task Group** and **WG1 Clinical and Safety Edits Task Group**: Recaps for these task groups can be found in the WG14 download materials.

New Business:

- The **WG14 2022-2023 Scope and Goals** were reviewed and approved as modified.

**Work Group 18 Specialty Pharmacy**

DERFs Reviewed:

- Pended DERF 001904 was approved.

Task Groups:

- The **Specialty Pharmacy Data Exchange Task Group** continued working on the Performance Metrics Standard, including structure and new fields. They discussed a possible beta implementation of the Specialty Pharmacy Data Reporting Standard. A pharmacy and manufacturer are willing to partner for a pilot, but the project is on hold until the pharmacy becomes a member of NCPDP.
- The **Benefit Coverage Identification Task Group** previously distributed a survey on specialty benefit coverage identification. The task group continues to look at regulatory compliance issues.
- The **Patient Consent Task Group** worked toward supporting the two-priority task group business cases within the NCPDP/HL7® FHIR® Specialty Medication Enrollment Implementation Guide (unsolicited consent transmission and consent request/response from the dispenser to the prescriber/clinic) along with consent notification during the encounter. The task group confirmed error corrections in the guide and reviewed with HL7® workgroup owners.
- The **Facilitation Access to Specialty Products Task Group** disbanded, having completed their work.
- The **Specialty Requirements for ePrescribing Task Group** did not meet this quarter. The task group leads were asked to attend the WG18: Patient Consent Task Group for review of DERF 001904 being submitted and attended the MC: REMS Workflow to Transaction Task Group meeting to consult on whether the NCPDP/HL7® FHIR® Specialty Medication Enrollment implementation guide could be utilized for REMS transactions.

Other Reportables:
- **WG10 Identification of Social Determinants of Health Task Group, WG11 Prior Authorization Workflow-to-Transaction Task Group, MC REMS Workflow-to-Transaction Task Group and MC Real Time Prescription Benefit Standard Task Group**: Recaps for these task groups can be found in the WG18 download materials.

**New Business:**
- Industry Update: An update on Value-Based Arrangements (VBA) was provided to the work group.
- The **WG18 2022-2023 Scope and Goals** were reviewed and approved as modified.

**Work Group 45 External Standards Assessment and Implementation Guidance**

**DERFs Reviewed:**
- DERF 001917 was approved as modified.

**Old Business:**
- Industry updates were provided for WEDI, NCPDP SNIP, CAQH CORE and X12.

**Task Groups:**
- **The Pharmacy and/or Combination ID Card Task Group** presented an updated version of the Pharmacy ID Card Fact Sheet for approval and publication. The update adds clarity that card issuing entities are responsible for state requirements.
- The **834/835 FAQ Task Group** did not meet this quarter.
- The **Document Revisions Task Group** did not meet this quarter, but a new version of the CARC mapping document was published. They will meet in August to discuss CARC changes.
- The **DSMO Task Group** received no DSMO requests for review.

**New Business:**
- The **WG45 Scope and Goals** were reviewed and approved as modified.

**MC Maintenance and Control**

**DERFs/ECLs**: 13 new and two pended DERFs/ECLs were reviewed (see WG1, WG11, WG18 and WG45).
- DERF 001901 was approved as modified.
- DERF 001904 was approved.
- DERF 001906/Emergency ECL 000374 was withdrawn.
- DERF 001907/ECL 000375 was pended.
- DERF 001908/ECL 000376 was pended.
- DERF 001909/ECL 000377 was approved.
- DERF 001910/ECL 000378 was approved.
- DERF 001911/ECL 000379 was approved with modifications.
- DERF 001912/ECL 000380 was approved as modified.
- DERF 001913 was approved as modified.
- DERF 001914 was approved.
- DERF 001915 was approved.
- DERF 001916 was approved as modified.
- DERF 001917 was approved as modified.
- DERF 001918 was approved.

**Old Business:**
- Received updates for:
  - Board of Trustees
  - SNIP Committee
Task Groups:

- **The Education/Legislation and Regulations Task Group** did not meet this quarter.
- **The Emergency Preparedness Task Group** discussed New York Department of Health issues, the Strategic National Stockpile drug review for the monkeypox vaccine and the requirements for pharmacists to prescribe Paxlovid for COVID-19 patients. The task group updated the *NCPDP Emergency Preparedness Guidance Document* to:
  - Add a sub-section for pediatric three dose vaccine under Section 10 COVID-19 Vaccine Considerations.
  - Modify FAQ 11.15 to support the scenarios of billing of dispensing an EUA oral antiviral regardless of who prescribes and of a single claim billing for drug dispensing and patient assessment when the pharmacist is the prescriber.
  - Add an FAQ for the temporary solution of using a claim billing transaction with a pseudo NDC for the scenario of a patient assessment when it is determined the EUA oral antiviral product cannot be prescribed.

The work group approved with modifications the updated guidance document.

- **The X12 TR3 Comment Consolidation Task Group** is on hiatus and did not meet this quarter.
- **The Real Time Prescription Benefit Standard (RTPB) Task Group** reviewed two DERFs impacting data elements used in the RTPB Standard and recommended modifications to the ECL value limitation for one of them. The task group drafted an FAQ for the RTPB Standard Implementation Recommendations document about DAW codes and interchangeable biosimilars for the interim until new field definition and ECL values descriptions are implemented. The FAQ was approved.
  - The **Consumer and Provider RTPB Standards Monitoring Sub-Task Group** completed its review of state legislation referencing consumer-facing RTPB and did not identify any gaps with the HL7® FHIR® CARIN Consumer Realtime Pharmacy Benefit Check Implementation Guide. The task group is waiting for CARIN Alliance to complete its review of the potential gaps previously identified between the Consumer RTPB Check Implementation Guide and the RTPB Standard.
  - The **Related RTPB Law Review Sub-Task Group** is on hiatus and did not meet this quarter.
- **The Digital Therapeutics Task Group** is resending their survey to members of the Digital Therapeutics Alliance (DTA) because initial response was lacking. As a follow-up to the new memorandum of understanding between NCPDP and DTA, the task group co-leads gave a presentation about NCPDP to a DTA work group.
- **The NDC Scarcity Task Group** requested a Stakeholders Action Group (SAG) for 2023 for the expansion of the labeler code from five digits to six-digits to clarify solutions to known issues, identify new issues which need to be addressed and determine what the stakeholders’ systems can and cannot accommodate. The task group also identified multiple issues and topics for discussion.
- **The Definition and Use of Quantity and Day Supply Task Group** created definitions for the types of days supply and quantity to explain their meaning and to have criteria for assigning discrete data elements to transactions. The task group evaluated the proposed definitions against the use cases and the purpose of the transaction where the type is used to ensure they fit.
- **The REMS Workflow to Transactions Task Group** continued to identify NCPDP transactions that could be used for the Risk Evaluation and Mitigation Strategy (REMS) process. The task group also heard a presentation of a pilot program by MITRE through CodeX for REMS transactions.
• The **NCPDP Standards Message Structure Harmonization Task Group** continued to review and analyze survey results in conjunction with preparing recommendations to present to the Standardization Committee.

• The **MC Prior Authorization Communication, Evaluation and Recommendations (PACER) Task Group** reviewed the SCRIPT Prior Authorization transactions. The task group also worked on a gap analysis of SCRIPT PAResult transaction versus Telecommunication Prior Authorization Request Only transaction.

• The **Barcode Utilization Task Group** created their scope statement and presented it for approval. The scope statement was approved. The task group also began updates to the *NCPDP GS1 DataMatrix White Paper*.

**New Business:**

• The MC WG 2022-2023 Scope and Goals were reviewed and approved as modified.

• The attendees heard a presentation from the FDA creating awareness of issues and concerns with the dosing and prescribing of Paxlovid.

• The attendees received recaps of each Work Group’s activities.